New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
15:54 EDTJNJ, BX, CG, DHRCarlyle in lead to buy J&J ortho clinical diagnostics unit, Reuters says
Johnson & Johnson (JNJ) currently views a bid from Carlyle Group (CG) for its ortho clinical diagnostics unit as superior to a rival bid from Blackstone Group (BX) in partnership with conglomerate Danaher (DHR), three people familiar with the matter said, according to Reuters, which added that the price of Carlyle's offer could not be learned. Reference Link
News For JNJ;CG;BX;DHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 14, 2015
10:06 EDTDHRHigh option volume stocks
Subscribe for More Information
09:45 EDTJNJJohnson & Johnson says Remicade market share in mid-single digits in Europe
Subscribe for More Information
09:37 EDTJNJJohnson & Johnson says acquisitions a priority, but divestitures still an option
09:33 EDTJNJJohnson & Johnson sees FY15 adjusted EPS $6.70--$6.80 on constant currency
Subscribe for More Information
09:32 EDTBXBlackstone portfolio company, Banyan Water expand partnership
LivCor, LLC, a portfolio company of global asset manager Blackstone, and Austin-based Banyan Water have expanded their partnership by deploying Banyan's Smart Irrigation solution at more multi-family properties in several states, including California.
09:31 EDTJNJJohnson & Johnson backs FY15 reported sales $75B-$76B, consensus $70.56B
Subscribe for More Information
09:30 EDTJNJJohnson & Johnson says consumer business seeing slower volumes in China
The company adds that it will not hesitate to divest businesses or assets that does not meet its profitability criteria. Anticipates at least one major product launch in each of the next three years in Vision Care business. Backs FY15 net interest expense $450M-$550M. Raises FY15 net other income to $2.2B-$2.3B from $2B-$2.1B. Comments taken from Q2 earnings conference call.
08:57 EDTDHRNetScout completes acquisition of Danaher's Communication Business
Subscribe for More Information
08:52 EDTDHRNetScout completes acquisition of Danaher's Communications Business
Subscribe for More Information
07:50 EDTJNJJohnson & Johnson reports Q2 Worldwide Consumer sales $3.5B
Subscribe for More Information
07:49 EDTJNJJohnson & Johnson raises FY15 adjusted EPS to $6.10-$6.20 from $6.04-$6.19
Subscribe for More Information
07:47 EDTJNJJohnson & Johnson reports Q2 Domestic sales down 2.4% to $8.91B
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q2 adjusted EPS $1.71, consensus $1.67
Subscribe for More Information
July 13, 2015
15:01 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:00 EDTJNJJohnson & Johnson July 100 straddle priced for 1.8% movement into Q2
14:05 EDTJNJEarnings Watch: Johnson & Johnson shares relatively flat since last earnings
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market opens on Tuesday, July 14, with a conference call scheduled for 8:30 am ET. Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. EXPECTATIONS: Analysts are looking for earnings per share of $1.68 on revenue of $17.76B, according to First Call. The consensus range for EPS is $1.54-$1.84 on revenue of $17.52B-$18.16B. LAST QUARTER: On April 14, Johnson & Johnson reported first quarter EPS of $1.56 on revenue of $17.37B. The company's Q1 results exceeded average analyst expectations of $1.54 for EPS and $17.31B for revenue. With its Q1 results, the drug giant lowered its EPS view for the year to $6.04-$6.19 from $6.12-$6.27 due to foreign currency headwinds, while maintaining its sales outlook of $75B-$76B. The company had worldwide consumer sales of $3.4B for the quarter which represented a decline of 4.7% versus the prior year due to a negative impact from foreign currency. Worldwide Pharmaceutical sales of $7.7B for the first quarter represented an increase of 3% versus the prior year with operational growth of 10.2% and a negative impact from currency of 7.2%. The strong operational sales results were driven by new products and the strength of core products. New products including Invokana/Invokamet, Xarelto and Imbruvica. STREET RESEARCH: On April 15, Wells Fargo said Johnson & Johnson's valuation appears attractive. The firm added that the growth outlook of the company's consumer business is improving, while its pharma unit has a growth profile that is well above average. The firm kept an Outperform rating on the stock. On April 20, Deutsche Bank added J&J to its short-term buy list. PRICE ACTION: Since reporting its Q1 results, Johnson & Johnson's stock is down fractionally, and it is currently trading up less than 1% in midday trading ahead of earnings.
13:29 EDTJNJJohnson & Johnson technical notes before earnings
Subscribe for More Information
12:46 EDTBXEarnings Watch: Wells Fargo CFO sees staying in higher end of efficiency range
Subscribe for More Information
11:47 EDTJNJFDA approves new drug to treat schizophrenia
The U.S. FDA announced that it has approved Rexulti tablets to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder. Rexulti is manufactured by Tokyo-based Otsuka Pharmaceutical. Novartis' (NVS) Clozaril is indicated to treat severely ill adult patients with schizophrenia who have not responded appropriately to standard antipsychotic treatment. Other atypical antipsychotics include Otsuka's Abilify, Pfizer's (PFE) Geodon, Janssen's (JNJ) Invega and Risperdal, Forest Labs' (ACT) Saphris, AstraZeneca's (AZN) Seroquel and Eli Lilly's (LLY) Zyprexa.
07:35 EDTCGCPA:18 acquires $17M building in Florida
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use